A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/07/2002	WO2002088143A2 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088140A1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
11/07/2002	WO2002088139A1 6h-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088138A1 Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
11/07/2002	WO2002088137A1 Pkb-3564 substance with neovascularization inhibitory activity
11/07/2002	WO2002088135A1 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans
11/07/2002	WO2002088132A1 Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-ht1aantagonists
11/07/2002	WO2002088131A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta[a]naphthalene
11/07/2002	WO2002088127A2 Triazolopyrimidines
11/07/2002	WO2002088124A2 Pyrazolo'1,5-a!pyridine derivatives
11/07/2002	WO2002088123A1 Chemical compounds
11/07/2002	WO2002088122A1 Heterocyclic compounds
11/07/2002	WO2002088118A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	WO2002088115A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
11/07/2002	WO2002088114A2 Heteroaryl ofefinic azacyclic and heteroaryl acetylenic azacyclic compounds for the treatment of cns disorders
11/07/2002	WO2002088113A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002	WO2002088111A1 Novel benzylpiperidine compound
11/07/2002	WO2002088110A1 Quinoline derivative having azolyl group and quinazoline derivative
11/07/2002	WO2002088109A1 Crystal of 6-[4-(4-pyridylamino)phenyl]-4, 5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate
11/07/2002	WO2002088108A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002	WO2002088107A1 Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
11/07/2002	WO2002088106A2 Cysteine protease inhibitors
11/07/2002	WO2002088101A2 Inhibitors of bace
11/07/2002	WO2002088100A2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088096A1 Compounds inhibiting cyclic nucleotide phosphodiesterases, preparation and uses thereof
11/07/2002	WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	WO2002088094A1 2-iminoimidazole derivatives (1)
11/07/2002	WO2002088093A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002	WO2002088092A1 2-iminoimidazole derivative (2)
11/07/2002	WO2002088090A2 Pyrazole derived kinase inhibitors
11/07/2002	WO2002088087A1 Novel heterocyclic derivatives
11/07/2002	WO2002088085A2 Methods and intermediates for preparing 4-aminoquinoline cetp inhibitors
11/07/2002	WO2002088084A1 Heterocyclic compound derivatives and medicines
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088078A2 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES
11/07/2002	WO2002088073A1 Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
11/07/2002	WO2002088071A1 20-hydroxyeicosatetraenoic acid production inhibitors
11/07/2002	WO2002088070A1 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
11/07/2002	WO2002088069A2 Compounds useful as intermediates for 4-aminoquinoline derivatives
11/07/2002	WO2002087700A1 Method, kit and device for the treatment of cosmetic skin conditions
11/07/2002	WO2002087621A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
11/07/2002	WO2002087620A1 Chondrogenesis promoters
11/07/2002	WO2002087619A1 Preventive/therapeutic method for cancer
11/07/2002	WO2002087618A1 Preventive/therapeutic method for cancer
11/07/2002	WO2002087617A1 Supplementary immunotherapeutics to be used after lung cancer removal
11/07/2002	WO2002087608A1 Novel pain relievers which are trp-channel inhibitors
11/07/2002	WO2002087604A2 Preparations containing a combination of vitamin e and afamin
11/07/2002	WO2002087603A1 Immunopotentiators
11/07/2002	WO2002087600A1 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
11/07/2002	WO2002087598A1 Improvements in and relating to the administration of copper to an animal
11/07/2002	WO2002087597A1 Oral delivery of macromolecules
11/07/2002	WO2002087596A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002	WO2002087595A1 Treating retinal or photoreceptor degenerative diseases
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087592A1 Injectable pamidronate disodium
11/07/2002	WO2002087591A2 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug
11/07/2002	WO2002087590A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
11/07/2002	WO2002087589A1 Medicine for inhibiting drug elimination pump
11/07/2002	WO2002087588A1 Amorphous cefditoren pivoxil composition and process for producing the same
11/07/2002	WO2002087586A1 Sustained release drug delivery system containing codrugs
11/07/2002	WO2002087585A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002	WO2002087584A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002	WO2002087583A2 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002	WO2002087582A1 Use of the opioid antagonist naltrexone to prevent and control side effects caused by opioids
11/07/2002	WO2002087581A1 Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
11/07/2002	WO2002087580A1 Abc expression promoters
11/07/2002	WO2002087579A1 Use of mangafodipir for treating oxidative stress effects
11/07/2002	WO2002087578A1 Remedial agent for chronic articular rheumatism
11/07/2002	WO2002087577A1 Medicines
11/07/2002	WO2002087576A1 The treatment of scarring and related conditions using ppar-gamma activators
11/07/2002	WO2002087575A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
11/07/2002	WO2002087574A2 Use of pyridoindolone derivatives for preparing anticancer medicines
11/07/2002	WO2002087573A1 Crf receptor antagonists
11/07/2002	WO2002087572A1 Triazole derivative solution preparations
11/07/2002	WO2002087571A1 Aromatase inhibitors as novel veterinary drugs
11/07/2002	WO2002087570A1 Composition comprising antifungal agents for treating vulvovaginitis and vaginosis
11/07/2002	WO2002087569A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002	WO2002087568A1 Utilization of anthranilic acid amides as a medicament for treating arrhythmias and pharmaceutical preparations that contain said compounds
11/07/2002	WO2002087567A2 Polymethoxylated flavones for treating insulin resistance
11/07/2002	WO2002087566A1 The use of enantiomeric pure escitalopram
11/07/2002	WO2002087565A1 Inhibition of pigmentation by inhibition of fatty acid synthase
11/07/2002	WO2002087564A1 Class of glaucoma drugs to enhance aqueous humor outflow and lower intra-ocular pressure
11/07/2002	WO2002087563A2 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
11/07/2002	WO2002087562A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	WO2002087561A1 Method of treating age-related vision impairment
11/07/2002	WO2002087560A1 Carboxylic acid such as citric acid for desinfecting or enhacing the production of blood products such as plasma, cryoprecipitate or/and platelet
11/07/2002	WO2002087559A1 Potassium channel opener
11/07/2002	WO2002087558A1 Pharmaceutical composition which reduces or eliminates drug abuse potential
11/07/2002	WO2002087557A1 Method for treating retina or photoreceptor degeneration
11/07/2002	WO2002087556A2 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
11/07/2002	WO2002087555A2 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
11/07/2002	WO2002087553A2 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
11/07/2002	WO2002087552A2 Androgen-mediated neuroprotection and uses thereof
11/07/2002	WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002	WO2002087547A1 An improved process for preparation of four-drug anti-tubercular fixed dose combination
11/07/2002	WO2002087546A2 Method for manufacturing a low dose pharmaceutical composition
11/07/2002	WO2002087545A1 Composition and methods for treatment of hyperplasia
11/07/2002	WO2002087543A1 Sustained release formulations for nifedipine, dextromethorphan, and danazol

1 ... 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 ... 7860